RT Journal Article
SR Electronic
T1 Effectiveness and safety of rivaroxaban for anticoagulation therapy in COVID-19
JF Saudi Medical Journal
JO Saudi Med J
FD Prince Sultan Military Medical City
SP 341
OP 348
DO 10.15537/smj.2024.45.4.20230728
VO 45
IS 4
A1 Shen, Xiangbo
A1 Qiu, Eryue
A1 Liu, Zhao
A1 Zhu, Xiaopeng
A1 Zeng, Yiqian
YR 2024
UL http://smj.org.sa/content/45/4/341.abstract
AB Objectives: To evaluate the effectiveness and safety of rivaroxaban anticoagulation in COVID-19 patients.Methods: PubMed, Embase, Cochrane Library electronic databases, and ClinicalTrials.gov were searched to identify all relevant randomized controlled trial studies from December 2019 to July 2023.Results: A total of 6 randomized controlled trials, which included a total of 3323 patients, were considered for evaluation. Overall, short-term all-cause mortality and hospitalization rates were not significantly different between the rivaroxaban and control groups. Thrombotic events were significantly reduced in the rivaroxaban prophylaxis group compared to the placebo control group. However, the reduction in thrombotic events was not significantly different between rivaroxaban therapy and heparin or low-molecular-weight heparin (LMWH). Rivaroxaban prophylaxis and the therapeutic dose may be associated with a higher rate of overall bleeding rate, but major bleeding rates did not differ substantially.Conclusion: Rivaroxaban may reduce thrombotic events in COVID-19 patients, but it does not appear to have an advantage over heparin or LMWH, and it may increase the risk of bleeding.INPLASY Reg. No.: INPLASY 202370097